UNSPSC 51262005: Carvedilol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C24H26N2O4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N9A00DJ8CM. Most nations, for tariff and trade purposes, schedule carvedilol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, CARVEDILOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC1CCCCC1OCCNCC(COC2CCCC3C2C4CCCCC4[NH]3)O.CL.

UNSPSC 51262005 Carvedilol hydrochloride is a Commodity code that in practice captures pharmaceutical procurement by state and local agencies, though recent opportunities tagged under it show minimal alignment with the code's specific drug name. State and local governments use codes in this family to procure medications and pharmaceutical products for public health programs, emergency response, and institutional healthcare delivery. The issuing bodies include county health departments, state health and human services commissions, and public safety agencies. Recent opportunities under this code reflect broader pharmaceutical sourcing rather than carvedilol-specific procurement — Seminole County, Florida solicited naloxone and drug deactivation systems through an IFB, while the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels. The scope of work spans emergency medication stockpiling, community health initiatives, and systemic pharmacy program restructuring.

Activity under this code appears concentrated in Florida and Texas based on recent postings. Seminole County's IFB for naloxone and deactivation systems (Solicitation IFB60459723LAS, due July 26, 2023) calls for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a fixed-fee basis with a two-year initial term and one-year renewal option. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription programs serving self-insured state employee health plans and public agencies outside existing PBM and GPO relationships, signaling a shift toward alternative pharmaceutical sourcing models. Both opportunities require vendors to comply with E-Verify, drug-free workplace certification, and applicable federal environmental and compliance standards. The code shows limited recent activity overall; the mismatch between the code's nominal scope (carvedilol hydrochloride, a specific beta-blocker) and the actual procurements (emergency narcotics and systemic pharmacy initiatives) suggests the code may not be capturing carvedilol-specific demand accurately or that state and local agencies are tagging broader pharmaceutical categories under this code number.